Literature DB >> 24668056

Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk.

Francesca Maffei1, Juan Manuel Zolezzi Moraga, Sabrina Angelini, Corrado Zenesini, Muriel Musti, Davide Festi, Giorgio Cantelli-Forti, Patrizia Hrelia.   

Abstract

The early detection of colorectal cancer (CRC) can significantly improve the prognosis of affected patients. The loss of genomic stability and the resulting gene alteration play an important role in the molecular pathological steps that occur early in tumorigenesis of CRC. Thus, the identification of non-invasive biomarkers, whose function may provide useful insights into critical early events in the CRC process, is of great interest. In this regard, micronucleus (MN) frequency in peripheral blood lymphocytes (PBL) has become one of the most established biomarkers for studying DNA damage in the human population. This study investigated the MN frequency in the PBL of 82 subjects (30 females and 52 males; aged 50-70 years) who were participating in a screening programme for CRC prevention. All 82 patients were positive in fecal occult blood tests and they were subsequently classified, according to colonoscopy and histological findings, as patients with CRC, patients with colon polyps or subjects without intestinal lesion, referred to as study controls. This study also examined the relationship between the plasma clastogenic activity and the frequency of micronuclei of the study population. The MN frequency was significantly higher in CRC patients than in both colon polyp patients (16.82±6.56 versus 12.23±1.88; P = 0.002) and controls (16.82±6.56 versus 8.00±1.77; P < 0.001). An increased MN frequency was detected in the lymphocytes of the polyp group in comparison to the control group, although this was lower than that observed in CRC patients (12.23±1.88 versus 8.00±1.77; P < 0.001). In the overall study population, the increase of MN frequency, which was observed in the lymphocytes of the subjects involved, was significantly associated with the clastogenic activity detected in their plasma (r = 0.594, P < 0.001). Overall, the results suggest that the MN test can become a promising biomarker for the early detection of CRC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668056     DOI: 10.1093/mutage/geu007

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  8 in total

1.  Correspondence: Abnormal Nuclear Variations in Response to Radiotherapy: As a Tool in Treatment Planning and Assessment of Prognosis.

Authors:  Laxman Khanal
Journal:  J Clin Diagn Res       Date:  2017-05-01

2.  Cytogenetic effects of radioiodine therapy: a 20-year follow-up study.

Authors:  Gordon K Livingston; Igor K Khvostunov; Eric Gregoire; Joan-Francesc Barquinero; Lin Shi; Satoshi Tashiro
Journal:  Radiat Environ Biophys       Date:  2016-03-25       Impact factor: 1.925

3.  Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas.

Authors:  Sanjeevani Arora; Hong Yan; Iltaeg Cho; Hua-Ying Fan; Biao Luo; Xiaowu Gai; Dale L Bodian; Joseph G Vockley; Yan Zhou; Elizabeth A Handorf; Brian L Egleston; Mark D Andrake; Emmanuelle Nicolas; Ilya G Serebriiskii; Timothy J Yen; Michael J Hall; Erica A Golemis; Greg H Enders
Journal:  Gastroenterology       Date:  2015-09-05       Impact factor: 22.682

4.  Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility.

Authors:  Claudia Bolognesi; Paolo Bruzzi; Viviana Gismondi; Samantha Volpi; Valeria Viassolo; Simona Pedemonte; Liliana Varesco
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

Review 5.  Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).

Authors:  Taxiarchis Konstantinos Nikolouzakis; Loukia Vassilopoulou; Persefoni Fragkiadaki; Theodoros Mariolis Sapsakos; Georgios Z Papadakis; Demetrios A Spandidos; Aristides M Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2018-03-21       Impact factor: 4.136

6.  Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer.

Authors:  Taxiarchis Konstantinos Nikolouzakis; Polychronis D Stivaktakis; Paraskevi Apalaki; Katerina Kalliantasi; Theodoros Mariolis Sapsakos; Demetrios A Spandidos; Aristidis Tsatsakis; John Souglakos; John Tsiaoussis
Journal:  Oncol Lett       Date:  2019-01-07       Impact factor: 2.967

7.  Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes.

Authors:  Taxiarchis Konstantinos Nikolouzakis; Elena Vakonaki; Polychronis D Stivaktakis; Athanasios Alegakis; Aikaterini Berdiaki; Nikolaos Razos; John Souglakos; Aristidis Tsatsakis; John Tsiaoussis
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

8.  Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.

Authors:  Gloria Ravegnini; Juan Manuel Zolezzi Moraga; Francesca Maffei; Muriel Musti; Corrado Zenesini; Vittorio Simeon; Giulia Sammarini; Davide Festi; Patrizia Hrelia; Sabrina Angelini
Journal:  Int J Mol Sci       Date:  2015-12-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.